Literature DB >> 7572146

Different kinetics of antibody responses between IgA and IgG classes in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection.

H Tsutsumi1, K Matsuda, H Yamazaki, P L Ogra, S Chiba.   

Abstract

The secretory antibody responses in 34 infants and children (20 days-17 months old) with lower respiratory tract disease following primary respiratory syncytial virus (RSV) infection were determined using a sensitive tissue culture enzyme linked immunosorbent assay. None of the patients in the acute phase showed IgA antibody responses. In contrast significant IgG antibody responses which were thought to be maternally derived were observed in infants younger than 2 months of age. In the convalescent phase sample, significantly high IgA antibody responses were observed in all patients except one, and there was no significant difference in magnitude of antibody activity between patients younger than 8 months and patients older than 8 months. However, IgG antibody responses in infants younger than 8 months were significantly lower than in subjects 8 to 17 months old. Notably, infants younger than 2 months developed no significant IgG antibody activity in the convalescent phase. These observations suggest that the antibody activity which contributes to recovery from primary infection by RSV in younger infants may be IgA rather than IgG class antibodies. These observations also suggest that the presumptive immunosuppression mediated by maternally derived antibodies may predominantly influence the IgG antibody response rather than the development of local IgA antibody activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572146     DOI: 10.1111/j.1442-200x.1995.tb03356.x

Source DB:  PubMed          Journal:  Acta Paediatr Jpn        ISSN: 0374-5600


  6 in total

Review 1.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

2.  A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.

Authors:  Fabián E Díaz; Mariana Guerra-Maupome; Paiton O McDonald; Daniela Rivera-Pérez; Alexis M Kalergis; Jodi L McGill
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

3.  Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf.

Authors:  Jodi L McGill; Sean M Kelly; Pankaj Kumar; Savannah Speckhart; Shannon L Haughney; Jamie Henningson; Balaji Narasimhan; Randy E Sacco
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

Review 4.  Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Authors:  Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

Review 5.  Antibody development for preventing the human respiratory syncytial virus pathology.

Authors:  Jorge A Soto; Nicolás M S Gálvez; Gaspar A Pacheco; Susan M Bueno; Alexis M Kalergis
Journal:  Mol Med       Date:  2020-04-17       Impact factor: 6.354

6.  Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years.

Authors:  Guy Berbers; Liesbeth Mollema; Fiona van der Klis; Gerco den Hartog; Rutger Schepp
Journal:  J Infect Dis       Date:  2021-07-15       Impact factor: 5.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.